Up to now, baclofen (a GABA(B) receptor agonist) has been used for the treatment of severe spasticity unresponsive to oral antispasmodics. Although in humans it is usually administered at 2 mg/ml, the dosage to be used in the treatment of other diseases is unknown. For this reason, it is important to determine the safe maximum dosage and toxicity at the clinically used concentration. Primary cortical neurons represent a useful model to test the safety of baclofen. We performed a colorimetric assay (MTT test) as well as electron microscopy investigations, to determine neuronal survival after the treatment with baclofen at a concentration of 2 and 4 mg/ml. Our results demonstrated that, in our experimental model, neither concentration affected neuronal survival. Considering the above results, we can conclude that at the used concentrations, this drug is safe and its clinical use should be encouraged. (c) 2006 Elsevier B.V. All rights reserved.

Baclofen and potential therapeutic use: Studies of neuronal survival

REGUZZONI, MARCELLA;PROTASONI, MARINA;FESCE, RICCARDO GIUSEPPE;PERES, ANTONIO;TOMEI, GIUSTINO
2006

Abstract

Up to now, baclofen (a GABA(B) receptor agonist) has been used for the treatment of severe spasticity unresponsive to oral antispasmodics. Although in humans it is usually administered at 2 mg/ml, the dosage to be used in the treatment of other diseases is unknown. For this reason, it is important to determine the safe maximum dosage and toxicity at the clinically used concentration. Primary cortical neurons represent a useful model to test the safety of baclofen. We performed a colorimetric assay (MTT test) as well as electron microscopy investigations, to determine neuronal survival after the treatment with baclofen at a concentration of 2 and 4 mg/ml. Our results demonstrated that, in our experimental model, neither concentration affected neuronal survival. Considering the above results, we can conclude that at the used concentrations, this drug is safe and its clinical use should be encouraged. (c) 2006 Elsevier B.V. All rights reserved.
Dario, A; Pisani, R; Sangiorgi, S; Soragna, A; Reguzzoni, Marcella; Protasoni, Marina; Pessina, F; Fesce, RICCARDO GIUSEPPE; Peres, Antonio; Tomei, Giustino
File in questo prodotto:
File Dimensione Formato  
Baclofen.pdf

non disponibili

Descrizione: PDF editoriale
Tipologia: Altro materiale allegato
Licenza: DRM non definito
Dimensione 563.25 kB
Formato Adobe PDF
563.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/1708469
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact